Login to Your Account



Soligenix Halts Phase III OrBec Study in GvHD: Stock Tanks

By Marie Powers


Friday, September 16, 2011
Soligenix Inc. (formerly DOR BioPharma Inc.) halted its confirmatory Phase III trial of orBec (oral beclomethasone dipropionate, or OBD) for acute gastrointestinal graft-vs.-host disease (GvHD) following stem cell transplant after an interim analysis by an independent data safety monitoring board concluded the study was "highly unlikely" to meet its predetermined efficacy endpoint. No safety concerns were raised.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription